Poseida Therapeutics (NASDAQ:PSTX) reported quarterly losses of $(0.74) per share. This is a 67.54 percent increase over losses of $(2.28) per share from the same period last year.
Related Posts
Morgan Stanley Maintains Overweight on Carrier Global, Lowers Price Target to $58
Morgan Stanley analyst Joshua Pokrzywinski maintains Carrier Global (NYSE:CARR) with a Overweight and lowers the price target from $60 to $58.
Argenx Announces U.S. FDA Acceptance Of Biologics License Application For Subcutaneous Efgartigimod In Generalized Myasthenia Gravis With Priority Review; PDUFA Date Is March 20, 2023
- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023
- Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at day
Roth Capital Maintains Neutral on AcuityAds Holdings, Lowers Price Target to $5
Roth Capital analyst Darren Aftahi maintains AcuityAds Holdings (NASDAQ:ATY) with a Neutral and lowers the price target from $7 to $5.